The latest medical news from HaemophiliaXPERT
Consultez Online Version
|
|
|
Welcome,
|
| Find hereafter the latest scientific publications from peer-reviewed journals focused on your area of expertise. |
|
| Publications on Friday June 19, 2026 |
| Inhibitor development according to FVIII concentrates in PUPs with severe hemophilia A: update from the PedNet registry |
| Journal of Thrombosis and Haemostasis 2026; AOP:10.1016/j.jtha.2026.04.031 |
Treatment of severe Hemophilia A (SHA) with FVIII concentrates is complicated by development of neutralizing inhibitors in about 30% during the first 50 exposure days (EDs). Despite extensive research,...
HTML Version |
PDF Version
|
Print the excerpt
|
| UK Experience of Children With Inhibitors in Severe Haemophilia B: A Report by the UKHCDO Paediatric Working Party. |
| Haemophilia (2026). |
The development of neutralising antibodies (inhibitors) against FIX is the most serious complication of treatment in severe haemophilia B (SHB), and given the overall rarity of inhibitor formation (5%-10%),...
HTML Version |
PDF Version
|
Print the excerpt
|
| Biomarkers as Diagnostic and Prognostic Tools for Hemophilic Arthropathy. |
| Hamostaseologie 2026 May |
Repeated joint bleeds cause hemophilic arthropathy, which can develop despite regular prophylaxis with clotting factors. Therefore, recognizing ongoing or subclinical bleeds is an important element of...
Read more
|
Free Full-text
|
| Hemophilia in the Era of Advanced Therapies: Structural Monitoring, the Role of Musculoskeletal Ultrasound, and a Proposed Multidisciplinary Care Model-A Structured Narrative Review. |
| Diagnostics (Basel, Switzerland) 2026 May; 16(11) |
Advances in hemophilia treatment, including extended half-life factor concentrates, non-replacement therapies, and gene therapy, have substantially reduced bleeding frequency and improved life expectancy....
Read more
|
Free Full-text
|
|
 |
|
|
Invite a colleague
|
Edit my profil
|
Unsubscribe
|
Sources and criteria
|
|
|
